Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-24-000068
Filing Date
2024-01-25
Accepted
2024-01-25 16:25:06
Documents
2
Group Members
ORBIMED CAPITAL GP VI LLCORBIMED CAPITAL LLCORBIMED GENESIS GP LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 ss2947877_sc13da.htm SC 13D/A 130545
2 JOINT FILING AGREEMENT ss2947877_ex9901.htm EX-99.1 7412
  Complete submission text file 0000947871-24-000068.txt   139593
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Subject) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92424 | Film No.: 24562506
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)